Skip to main content
Premium Trial:

Request an Annual Quote

Immunicon Inks Biomarker Assay, Lab Services Deal with Merck Serono

Immunicon this week announced that it has signed a laboratory services and biomarker assay development pact with Merck Serono, the Geneva-based unit of Germany’s Merck KGaA.
 
Under the deal, Immunicon will develop specialized biomarker assays based on circulating tumor cells for an early clinical drug study. Immunicon said the new assays could potentially help doctors identify patients who have a high probability of responding to the drug being developed by Merck Serono.
 
“The ability to interrogate the extremely rare circulating cells once isolated from peripheral blood gives unprecedented opportunities to see real-time what is happening with tumor cells in patients upon exposure to investigational drugs,” Leon Terstappen, chief scientific officer of Immunicon, said in a statement.
 
Terms of the alliance were not disclosed.

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.